scispace - formally typeset
C

Christina Wang

Researcher at Los Angeles Biomedical Research Institute

Publications -  450
Citations -  30621

Christina Wang is an academic researcher from Los Angeles Biomedical Research Institute. The author has contributed to research in topics: Testosterone (patch) & Sperm. The author has an hindex of 88, co-authored 422 publications receiving 27941 citations. Previous affiliations of Christina Wang include Queen Mary University of London & Cedars-Sinai Medical Center.

Papers
More filters
Journal ArticleDOI

Role of Caspase 2 in Apoptotic Signaling in Primate and Murine Germ Cells

TL;DR: The results show that caspase 2 is activated in male germ cells undergoing apoptosis in nonhuman primates after heat stress, hormonal deprivation, or after combined interventions.
Journal ArticleDOI

Graded testosterone infusions distinguish gonadotropin negative-feedback responsiveness in Asian and white men--a Clinical Research Center study.

TL;DR: The data suggest that, compared with white men, Asian men respond earlier and with more marked suppression of pulsatile LH secretion to ramped testosterone infusions, and the elevated basal serum FSH concentrations and more irregular FSH release pattern observed in Asian men may suggest a small relative decrease in spermatogenic reserve and/or gonadal negative feedback.
Journal ArticleDOI

Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial

TL;DR: A transdermal gel-based male hormonal contraceptive regimen, containing testosterone and Nestorone gels, would be acceptable to study participants as a primary contraceptive method and could provide a reversible, effective method of contraception that is appealing to men.
Journal ArticleDOI

Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent.

TL;DR: The potential beneficial effect of less prostate growth after DHT requires substantiation and, if true, must be balanced against any negative effects that might occur on bone, lipids and sexuality when a pure androgen replaces treatment with an aromatizable androgen.
Journal ArticleDOI

Long Acting Testosterone Undecanoate Therapy in Men With Hypogonadism: Results of a Pharmacokinetic Clinical Study

TL;DR: This 24-week clinical study demonstrated that 750 mg testosterone undecanoate depot injection administered intramuscularly at 0, 4 and 14 weeks achieves serum testosterone levels in the normal range during a 10-week dosing interval.